The Evolving Management of Psoriatic Disease: A Guide for Managed Care and Specialty Pharmacy Professionals Web Activity


John Fox, MD, MHA
Chief Boundary Spanner
Foxworthy Healthcare Consulting, PLLC 
Click here for biography

Jamie McConaha, PharmD, NCTTP, BCACP, CDE
Associate Professor of Pharmacy Practice
Duquesne University, Mylan School of Pharmacy
Click here for biography

Michael Zeglinski, RPh
Optum Specialty & Infusion Pharmacies
Click here for biography

Target Audience

Statement of Need/Program Overview
Psoriasis and psoriatic arthritis present a significant clinical and humanistic burden to patients and managed care/specialty pharmacy organizations. Patients diagnosed with psoriatic disease are subject to increased mortality and functional disability which can lead to significant impairment of QoL and increased use of health care resources. Fortunately, there has been a marked increase in the number of safe and effective therapies to the disease. As a result, managed care and specialty pharmacy decision makers are challenged to match patients with the most appropriate therapeutic option. This task is complicated by the high prevalence of multiple chronic comorbid conditions as well as poor adherence to prescribed therapy; all of which must be addressed in order to achieve successful outcomes. The pathologic complexity of psoriatic disease and its comorbidities often requires collaborative multidisciplinary care. Improved awareness of therapeutic options available to manage the spectrum of pathologic challenges confronted by patients with psoriatic disease will enable managed care and specialty pharmacy professionals to improve patient quality of life and clinical outcomes.

Educational Objectives 
At the conclusion of this activity, participants should be able to demonstrate improved ability to: 


Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Impact Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-21-2636-H01-P
Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Interprofessional Continuing Education

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.


Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies.  All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Name of Faculty Reported Financial Relationship
John Fox, MD, MHA John Fox, MD, MHA has nothing to disclose.
Jamie McConaha, PharmD, NCTTP, BCACP, CDE Jamie McConaha, PharmD, NCTTP, BCACP, CDE has nothing to disclose.
Michael Zeglinski, RPh Michael Zeglinski, RPh has nothing to disclose.

The PIM planners and others have nothing to disclose.
The Impact Education, LLC® planners and others have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating and receiving CME/CE credit for this activity. During the period of accreditation participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, a certificate will be made available immediately to download and print.

For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account. Credit must be uploaded to CPE Monitor within 30 days.


There is no fee for this educational activity.